EGFR and cancer: Basic FGF, HGF, IGF, and NRG can rescue cancer cells from the EGFR TKI erlotinib4, so multi-target BP3-Fc constructs may inhibit growth factor rescue by all four growth factors and improve the efficacy of EGFR inhibitors.